First Real-World Study Reveals Patient Experience on Sympazan
In a retrospective EHR cohort spanning 2015–2024, Stanford Health Care identified 181 patients with epilepsy treated with clobazam oral...
eClinical Tech News
Kalaris Launches Promising New Trial for Macular Degeneration
Kalaris has opened enrollment for a Phase 1b/2 multiple-ascending-dose study of TH103 in neovascular AMD, targeting up to 80...
Spyre Doses First Patient in Phase 2 Rheumatic Disease Trial
Spyre Therapeutics has dosed the first patient in SKYWAY, a randomized, placebo-controlled Phase 2 basket trial of SPY072, an...
What Happened In The Efzofitimod Sarcoidosis Phase 3 Study
Efzofitimod missed the primary endpoint in the Phase 3 EFZO-FIT study, reducing mean daily oral corticosteroid dose at week...
Valuable Insight: Breast Cancer ADC Market & Trials to 2030
More than 100 antibody-drug conjugates (ADCs) targeting breast cancer are in clinical development, with use expanding from late-line metastatic...
Pasithea NF1 Trial Advances to Cohort 2 on Positive Safety
No dose-limiting toxicities were observed in the first three patients treated with PAS-004 at the initial dose in Pasithea’s...
Eye-opening Study: Patient Confusion Over Health Care Titles
Only 9% of more than 1,000 California adults correctly matched a healthcare practitioner’s title to the level of training...
Belite Bio Completes Phase 3 Stargardt Disease Trial
Belite Bio has completed the last subject visit in its pivotal Phase 3 DRAGON trial of tinlarebant for adolescent...
Successful Phase 1 Study for New Alzheimer’s Drug GAL-101
Galimedix reported completion of a Phase 1 study of oral GAL-101 in more than 100 healthy volunteers, showing the...
HCW’s T-Cell Engager Sees Remarkable Primate Study Results
In preclinical testing, a subcutaneously administered, tissue factor–targeting T‑cell engager from HCW Biologics was well tolerated in non‑human primates...